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INTRODUCTION
Daptomycin is a lipopeptide antimicrobial agent,
first described in the early 1980s, but not devel-
oped for clinical use until more recently in
response to increased resistance to other agents.
Daptomycin was registered by the European
Medicines Agency (EMEA) in November 2005
for skin and soft-tissue infections caused by
Staphylococcus spp. and Streptococcus spp., with
the exception of Streptococcus pneumoniae. This
technical note is based on the daptomycin ration-
ale document (available on the EUCAST website,
http://www.eucast.org). The rationale document
includes more details, as well as published refer-
ences related to the selection of EUCAST break-
points.
DOSAGE
EUCAST has determined clinical breakpoints for
the parenteral use of daptomycin 250 mg · 1.
Daptomycin has not been licensed previously in
Europe, so there is no history of differences in
dosage among different European countries.
MIC DISTRIBUTIONS
The daptomycin MICs for wild-type staphylo-
cocci and streptococci are £ 1mg ⁄L. The epidemi-
ological cut-off value was set at 1 mg ⁄L for
staphylococci, at 0.25, 0.5 and 1 mg ⁄L for strep-
tococci, depending on the species, and at 4 mg ⁄L
for both Enterococcus faecalis and Enterococcus
faecium (see http://www.eucast.org).
ESTABLISHED BREAKPOINTS
None of the European breakpoint committees
recommended breakpoints for daptomycin before
the establishment of the EUCAST breakpoint.
PHARMACOKINETIC DATA
Based on a standard once-daily parenteral dose of
4 mg ⁄ kg ⁄day, the pharmacokinetic data used to
evaluate daptomycin are shown in Table 1.
PHARMACODYNAMIC DATA
The pharmacodynamic data are summarised in
Table 2. There is considerable variation in the
pharmacodynamic target (AUC/MIC) required
for antibacterial effect in different studies. The
total drug AUC ⁄MIC for bacteriostatic effect
against Staphylococcus aureus is 438 ± 67 (range
120–537). If a two-log reduction in bacterial count
after 24 h dosing is chosen as the antibacterial
effect endpoint, the AUC/MIC target increases
more than two-fold. This higher target may be
more appropriate for inpatient intravenous ther-
apy; hence, the target selected is favourable to the
drug.
Monte Carlo simulation was performed based
on the parameter values listed in Table 1 since
Table 1. Pharmacokinetic data for daptomycin
Parameter Data
Dosage 4 mg ⁄ kg ⁄day (250 mg · 1) IV
Cmax (mg ⁄L) 57
Cmin (mg ⁄L) Not defined
Total body clearance (L ⁄h), mean (range) 0.86 (0.41–2.19)
T ½ (h), mean (range) 8.3 (4.64–48.01)
AUC24 h (mg.h ⁄L), mean (range) 400.8 (160.6–1143.7)
Fraction unbound (%) 8–10
Volume of distribution (L) 9.7 (5.1–32.8)
IV, intravenous.
Table 2. Pharmacodynamic data for daptomycin
Pharmacodynamic parameter Staphylococci Streptococci
AUC ⁄MIC for stasis 250–550 75–237
AUC ⁄MIC for 2 log drop 800–4000 157–815
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AUC distributions from neither volunteers nor
patients were available. Using a mean target
AUC ⁄MIC of 438, a probability of target attain-
ment of 100 is obtained for MICs of £ 0.5 mg/L
(Table 3). A pharmacodynamic susceptible break-
point of £ 0.5 mg ⁄L is therefore most appropriate.
If a lower AUC ⁄MIC target for staphylococci and
streptococci was used, as in some publications
and in additional data supplied by the manufac-
turer, a susceptibility breakpoint of £ 1 mg ⁄L
would be appropriate.
CLINICAL EFFICACY
Clinical efficacy data for staphylococci and strep-
tococci indicate eradication of the organisms in
80% of patients (similar to comparator treat-
ments) and no difference in eradication rates for
strains with different MICs £ 0.5 mg ⁄L. No data
are available for strains with MICs > 0.5 mg ⁄L.
BREAKPOINTS
Breakpoints are summarised in Table 4.
Non-species-related breakpoints
Non-species-related breakpoints are generally
determined on the basis of Pk ⁄Pd data and are
independent of MIC distributions of specific spe-
cies. The non-species-related breakpoints are for
use only with species for which specific break-
points are not given. Pharmacodynamic data sug-
gest a non-species-related breakpoint in the region
of 0.5 or 1 mg ⁄L for daptomycin, but as there is
insufficient evidence related to infections other
than those caused by staphylococci and strepto-
cocci, no non-species-specific breakpoint is given.
Table 3. Monte Carlo simulation of target attainment for
daptomycin 4 mg ⁄ kg ⁄day
Daptomycin
MIC (mg ⁄L)
Probability of target attainment with an AUC ⁄MIC target
of
373
(– one standard
deviation)
438
(mean)
503
(+ one standard
deviation)
‡ 4 0 0 0
2 0 0 0
1 96.8 77.2 42.9
0.5 100.0 100.0 100.0
£ 0.25 100.0 100.0 100.0
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Species-related breakpoints
For Staph. aureus, coagulase-negative staphylo-
cocci and streptococci, the wild-type distributions
of MICs range up to 1 mg ⁄L. Hence a susceptible
breakpoint of 1 mg ⁄L would render wild-type
Staphylococcus spp. and Streptococcus spp. suscept-
ible to daptomycin, would be compatible with the
pharmacodynamic and clinical data, and would
not divide wild-type populations. Resistant iso-
lates are rare, but MICs are reproducible for the
few isolates of Staph. aureus with MICs ‡ 2 mg ⁄L.
Therefore the following breakpoints are sugges-
ted for staphylococci and streptococci:
Susceptible £ 1 mg ⁄L
Intermediate -
Resistant > 1 mg ⁄L
Isolates with MICs above the resistant break-
point are rare. The identification and susceptibil-
ity tests on any such isolate must be repeated and,
if the result is confirmed, the isolate should be
sent to a reference laboratory. Until there is
evidence regarding clinical response, such isolates
should be reported as resistant.
Species without breakpoints
No breakpoint is given for enterococci, as true
skin and soft-tissue infections with enterococci are
rare and their presence may more likely reflect
colonisation. There is insufficient clinical evidence
to set a breakpoint for enterococci. There is also
insufficient evidence to determine whether Strep.
pneumoniae would be an appropriate target.
Daptomycin is not active against Enterobacte-
riaceae, Pseudomonas spp., Acinetobacter spp., Hae-
mophilus spp., Moraxella spp., Neisseria spp. or
anaerobic bacteria.
Additional comment
Daptomycin activity is markedly affected in vitro
by the concentration of calcium ions, and there
are unresolved questions concerning routine test-
ing of susceptibility to daptomycin. At present,
EUCAST recommends that the MIC must be
determined to allow susceptibility categorisation.
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